aquestive
therapeutics
signs
royalty
monetization
agreement
marathon
asset
management
million
receives
million
proceeds
closing
potential
million
additional
proceeds
reduces
outstanding
debt
million
warren
globe
newswire
aquestive
therapeutics
nasdaq
aqst
pharmaceutical
company
focused
developing
commercializing
differentiated
products
address
patients
unmet
needs
solve
therapeutic
problems
announced
today
entered
royalty
monetization
agreement
affiliate
marathon
asset
management
leading
global
investment
firm
marathon
result
proceeds
company
million
exchange
funding
marathon
entitled
receive
royalties
payments
due
aquestive
license
agreement
sunovion
pharmaceuticals
sunovion
result
sunovion
commercialization
apomorphine
hci
sublingual
film
acute
intermittent
treatment
episodes
patients
parkinson
disease
net
proceeds
transaction
used
repay
certain
senior
notes
fund
company
ongoing
development
commercialization
proprietary
product
pipeline
candidates
well
working
capital
purposes
kynmobi
received
approval
food
drug
administration
fda
may
terms
agreement
aquestive
receive
million
closing
eligible
receive
million
contingent
payments
various
points
beginning
early
fourth
quarter
based
achievement
certain
worldwide
royalty
targets
certain
commercial
milestones
transaction
anticipated
close
later
month
upfront
net
proceeds
monetization
company
repay
million
senior
notes
issue
million
new
senior
notes
lieu
paying
prepayment
premium
early
repayment
senior
notes
bringing
outstanding
senior
notes
million
aggregate
addition
holders
senior
notes
extended
december
company
ability
access
company
option
million
senior
notes
company
senior
debt
indenture
first
million
senior
notes
represents
commitment
amount
current
holders
senior
notes
contingent
upon
fda
approval
company
product
candidate
diazepam
buccal
film
management
seizure
clusters
second
million
senior
notes
represents
right
company
option
market
current
senior
note
holders
lenders
additional
senior
notes
amount
contingent
upon
fda
approval
libervant
market
access
extent
accessed
company
company
grant
warrants
purchase
shares
company
common
stock
exercise
price
calculated
based
volume
weighted
average
closing
price
company
common
stock
time
senior
notes
issued
addition
upon
closing
transaction
company
issue
warrants
purchase
shares
company
common
stock
prior
closing
financing
marathon
provides
aquestive
immediate
substantial
capital
reduce
debt
advance
key
initiatives
company
including
supporting
fda
approval
libervant
ongoing
clinical
development
oral
sublingual
formulation
delivering
systemic
epinephrine
stated
keith
kendall
president
chief
executive
officer
aquestive
capital
transaction
extends
cash
runway
third
quarter
possibly
beyond
additionally
extension
opportunity
access
million
additional
notes
senior
credit
facility
represents
significant
additional
capital
potentially
available
company
early
transaction
demonstrates
strong
value
technology
bringing
therapeutic
solutions
address
patients
unmet
needs
delighted
partnered
marathon
asset
management
senior
lenders
important
milestone
aquestive
concluded
kendall
investment
allows
aquestive
efficiently
finance
advancement
array
innovative
differentiated
therapies
potential
meaningfully
benefit
patients
said
bruce
richards
chairman
chief
executive
officer
marathon
pleased
able
support
efforts
delivering
attractive
uncorrelated
returns
investors
continue
build
success
healthcare
financing
space
particular
royalty
monetization
glad
structured
financing
enabled
aquestive
pursue
developmental
goals
look
forward
successful
working
relationship
impact
kynmobi
people
living
parkinson
disease
positive
development
stated
evan
bedil
managing
director
head
healthcare
credit
royalty
monetization
marathon
morgan
stanley
llc
acted
sole
structuring
agent
dechert
llp
acted
special
transaction
counsel
aquestive
transaction
aquestive
therapeutics
aquestive
therapeutics
pharmaceutical
company
applies
innovative
technology
solve
therapeutic
problems
improve
medicines
patients
aquestive
advancing
proprietary
product
pipeline
treat
cns
conditions
provide
alternatives
invasively
administered
standard
care
therapies
company
also
collaborates
pharmaceutical
companies
bring
new
molecules
market
using
proprietary
technologies
like
proven
capabilities
drug
development
commercialization
marathon
marathon
asset
management
new
global
investment
advisor
approximately
billion
aum
firm
found
louis
hanover
bruce
richards
employs
professionals
marathon
corporate
headquarters
new
york
city
international
offices
london
tokyo
marathon
registered
investment
adviser
securities
exchange
commission
information
please
visit
company
web
site
statement
press
release
includes
statements
within
meaning
private
securities
litigation
reform
act
words
believe
anticipate
plan
expect
estimate
intend
may
negative
terms
similar
expressions
intended
identify
statements
statements
include
limited
statements
regarding
therapeutic
benefits
plans
objectives
regulatory
approvals
libervant
ability
address
concerns
identified
fda
complete
response
letter
dated
september
regarding
new
drug
application
libervant
obtain
fda
approval
libervant
market
access
ability
obtain
fda
approval
advance
libervant
product
candidates
market
growth
future
financial
operating
results
financial
position
regulatory
approval
pathway
clinical
trial
timing
plans
competitors
orphan
drug
approval
resulting
drug
exclusivity
products
products
competitors
liquidity
cash
requirements
cash
funding
cash
burn
business
strategies
market
opportunities
statements
historical
facts
statements
also
subject
uncertain
impact
global
pandemic
business
including
respect
clinical
trials
including
site
initiation
patient
enrollment
timing
adequacy
clinical
trials
regulatory
submissions
regulatory
reviews
approvals
product
candidates
pharmaceutical
ingredient
raw
materials
supply
chain
manufacture
distribution
sale
demand
products
liquidity
availability
capital
resources
customer
demand
products
services
customers
ability
pay
goods
services
ongoing
availability
appropriate
labor
force
skilled
professionals
given
uncertainties
company
unable
provide
assurance
operations
maintained
planned
prior
pandemic
statements
based
current
expectations
beliefs
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
described
statements
risks
uncertainties
include
limited
risks
associated
company
development
work
including
delays
changes
timing
cost
success
product
development
activities
clinical
trials
plans
risk
delays
fda
approval
libervant
drug
candidates
failure
receive
approval
risk
ability
demonstrate
fda
clinical
superiority
within
meaning
fda
regulations
drug
candidate
libervant
relative
diazepam
rectal
gel
nasal
spray
products
including
establishing
major
contribution
patient
care
within
meaning
fda
regulations
relative
approved
products
well
risks
related
potential
pathways
positions
may
future
advanced
fda
overcome
seven
year
orphan
drug
exclusivity
granted
fda
approved
nasal
spray
product
competitor
assurance
successful
risk
competitor
obtains
fda
orphan
drug
exclusivity
product
active
moiety
drug
products
seeking
fda
approval
earlier
approved
competitor
orphan
drug
blocks
product
candidates
seven
years
indication
risk
inherent
commercializing
new
product
including
technology
risks
financial
risks
market
risks
implementation
risks
regulatory
limitations
risks
consummating
monetization
transaction
kynmobi
risks
uncertainties
concerning
royalty
revenue
stream
kynmobi
achievement
royalty
targets
worldwide
jurisdiction
certain
commercial
targets
required
contingent
payments
monetization
transaction
sufficiency
net
proceeds
monetization
transaction
satisfaction
compliance
senior
notes
obligations
applicable
funding
company
operations
risk
development
sales
marketing
capabilities
risk
legal
costs
associated
outcome
patent
litigation
challenging
third
party
risk
generic
sale
proprietary
products
risk
sufficient
capital
cash
resources
including
access
available
debt
equity
financing
revenues
operations
satisfy
longer
term
cash
requirements
cash
needs
times
amounts
needed
risk
failure
satisfy
financial
debt
covenants
default
risk
related
government
claims
indivior
license
manufacture
sell
accounts
substantial
part
current
operating
revenues
risk
associated
indivior
cessation
production
authorized
generic
buprenorphine
naloxone
film
product
including
impact
loss
orders
authorized
generic
product
risk
eroding
market
share
suboxone
risk
sunsetting
product
risks
related
outsourcing
certain
marketing
operational
staff
functions
third
parties
risk
rate
degree
market
acceptance
product
product
candidates
success
competing
products
including
generics
risk
size
growth
product
markets
risks
compliance
fda
governmental
customer
requirements
manufacturing
facilities
risks
associated
intellectual
property
rights
infringement
claims
relating
company
products
risk
unexpected
patent
developments
impact
existing
future
legislation
regulatory
provisions
product
exclusivity
legislation
regulatory
actions
affecting
pharmaceutical
product
pricing
reimbursement
access
claims
risks
may
arise
regarding
safety
efficacy
company
products
product
candidates
risk
loss
significant
customers
risks
related
legal
proceedings
including
patent
infringement
investigative
antitrust
litigation
matters
changes
government
laws
regulations
risk
product
recalls
withdrawals
uncertainties
related
general
economic
political
business
industry
regulatory
market
conditions
unusual
items
uncertainties
affecting
company
described
risk
factors
section
sections
included
annual
report
form
quarterly
reports
form
current
reports
form
filed
securities
exchange
commission
sec
given
uncertainties
place
undue
reliance
statements
speak
date
made
subsequent
statements
attributable
us
person
acting
behalf
expressly
qualified
entirety
cautionary
statement
company
assumes
obligation
update
statements
outlook
guidance
date
press
release
whether
result
new
information
future
events
otherwise
except
may
required
applicable
law
aquestive
logo
registered
trademarks
aquestive
therapeutics
registered
trademarks
referenced
herein
property
respective
owners
aquestive
investor
inquiries
westwicke
icr
company
stephanie
carrington
marathon
media
inquiries
prosek
partners
josh
clarkson
jclarkson
